Hormonal Changes in Aging
Linas JuozėnasShare
Hormonal Changes in Aging
Understand menopause, testosterone and body composition without reducing your health to a hormone number.
Changes in hormones can affect how the body feels and functions. Understanding the particular change helps you choose useful support, recognise symptoms that deserve assessment and weigh treatment on its actual benefits and risks.
This guide connects the science with everyday decisions about strength, bone health, sleep, symptoms and care. Menopause and testosterone deficiency in men follow different patterns, so each deserves a clear explanation.
A symptom, a laboratory result and a change in everyday function provide different information.
Relieving symptoms, treating a deficiency and protecting bone health require specific decisions.
Support strength, nourishment, recovery and the activities that make life satisfying.
Hormones and the whole person
Hormones are chemical signals that help coordinate functions across the body. Estrogens, progesterone and testosterone contribute to reproductive health and also influence tissues such as bone and muscle. Their effects depend on the wider biological and clinical context.
Midlife can bring hormonal change alongside changes in sleep, work, activity, illness, medication and caring responsibilities. Several influences can be present at once. Naming a hormone does not establish that it explains every symptom or determine what treatment is appropriate.
Two different situations need different language
Menopause marks the end of ovarian menstrual cycling and is usually identified retrospectively. Testosterone levels in men can change with age and health, but there is no universal male event that mirrors the final menstrual period.[1][2]
The term andropause is sometimes used in public discussion. It can be misleading when it suggests that all men experience the same timed hormone failure. Clinicians instead assess whether a person has a particular form of hypogonadism: inadequate sex-hormone production or function with the relevant clinical findings.
| Question | Menopause and perimenopause | Possible testosterone deficiency in men |
|---|---|---|
| What is changing? | Ovarian function and menstrual cycling change through a reproductive transition. | Testosterone production may be affected by testicular or pituitary disease, other health conditions, medicines or age-related factors. |
| Is it universal? | Natural menopause is an expected life stage for people with ovaries who reach it; timing and symptoms vary. | Clinically significant deficiency is not an inevitable diagnosis for every older man. |
| How is it assessed? | Menstrual history, age, symptoms and circumstances guide assessment; hormone tests are useful in selected situations. | Relevant symptoms and consistently low testosterone results must be considered together, followed by evaluation of the cause. |
| What is treatment trying to do? | Address troublesome symptoms and, in particular situations, the consequences of early hormone loss or bone risk. | Treat an established deficiency and its relevant effects while considering contraindications, fertility and monitoring. |
Start with what has changed in your life
“I wake repeatedly with night sweats” is a more useful starting description than “my hormones are broken.” So is “my periods have changed,” “sexual desire has declined” or “a familiar task has become more difficult.” A specific description makes it easier to decide what needs investigating.
Keep the result you want in view. It may be sleeping more comfortably, reducing pain during sex, returning to an activity or understanding a test result. A good plan should connect those priorities with appropriate evidence and care.
Hormonal changes do not reduce a person’s worth, competence or right to be heard. Support should make daily life more manageable while respecting the person’s own preferences.
Menopause and perimenopause
Natural menopause is generally recognised after 12 consecutive months without a menstrual period, when there is no other obvious cause and the absence is not explained by an intervention. It most often occurs between ages 45 and 55. Perimenopause describes the surrounding transition, during which menstrual patterns and symptoms may change.[1]
The final menstrual period is a point identified afterwards. Symptoms may begin before it and continue afterwards. You do not need to wait until a full year has passed before asking for help with a problem.
Hormones fluctuate before settling at a different pattern
The transition is not simply a smooth daily fall in estrogen. Ovulation becomes less predictable, progesterone patterns change and estrogen can fluctuate substantially before remaining lower after menopause. The signals involved in ovarian regulation also change.[3]
That variability helps explain why one isolated hormone result may not describe the whole transition. The reason for testing matters more than the size of the test panel.
The menstrual history may be harder to interpret
Hormonal contraception, other medicines and surgery can change bleeding patterns. Removal of the uterus stops menstrual bleeding but does not necessarily remove the ovaries. Removal of both ovaries before natural menopause creates a different and more abrupt hormonal situation.
Tell the clinician which organs were removed in any surgery and which treatments you use. If you are unsure, a surgical or medication record may help clarify the history. The absence of bleeding alone cannot answer every question in those circumstances.
Earlier ovarian insufficiency needs its own care
Premature ovarian insufficiency (POI) occurs before age 40 and requires clinical assessment and biochemical confirmation. It is not simply ordinary midlife menopause happening on an earlier calendar. The international POI guideline addresses hormone treatment, bone health, fertility and psychological support.[4]
For POI, hormone therapy is generally recommended until the usual age of menopause when appropriate, including for longer-term health rather than only symptom relief. The recommendation and treatment choice depend on the individual situation. Intermittent ovarian activity may occur, and hormone replacement itself is not contraception.[4]
Menopause between ages 40 and 44 is usually described as early menopause. If periods become persistently irregular or stop at a younger age, seek an explanation rather than assuming that the change needs no assessment.
Make room for different experiences
Some people have relatively little disruption; others have symptoms that substantially affect sleep, work, intimacy or daily activity. The intensity of another person’s experience does not determine whether yours deserves attention.
People with different gender identities may also experience menopause or have relevant effects from surgery and hormone treatment. The useful clinical details are the anatomy, treatments, symptoms and goals that apply to the individual.
Symptoms and appropriate assessment
Common experiences around menopause include hot flushes, night sweats, changes in sleep, vaginal dryness and changes in mood. Symptoms can overlap with other health problems, so they should be interpreted alongside the menstrual and medical history.[5]
A symptom can be real and disruptive even when its cause is not yet clear. Assessment should help identify what is happening and which options may help.
Keep a short, useful record
For a few representative days or weeks, note the main symptom, its timing, any bleeding pattern and the effect on ordinary life. Include current medicines and any recent changes. You do not need to record every sensation.
Examples of useful details include waking with sweating several nights each week, discomfort that affects sexual activity, or bleeding that has become substantially heavier. These descriptions help a clinician ask more focused questions.
Testing should answer a clinical question
For typical perimenopause or menopause after age 45, the European Society of Endocrinology advises that routine hormone testing is unnecessary.[3]
A clinician may investigate another cause when the history warrants it. A thyroid problem, anaemia, a sleep disorder or another illness should not be overlooked simply because menopause is also plausible.
Bleeding deserves a specific conversation
Irregular bleeding can occur during the transition, but very heavy, persistent or otherwise unusual bleeding should be assessed. Bleeding after menopause needs medical evaluation. Bleeding while using hormone therapy should be discussed according to its pattern and timing; it is not something to dismiss automatically as an expected hormonal effect.[3]
Tell the clinician whether you use contraception or hormone therapy and when it was started or changed. That information helps determine the appropriate investigation.
Address sexual and urinary discomfort directly
The genitourinary syndrome of menopause describes changes that can include vaginal dryness, irritation, discomfort with sex and urinary symptoms. Suitable treatments may include lubricants, moisturisers or specific prescription treatments, depending on the problem.[6]
These symptoms are worth discussing even if you do not have hot flushes. They do not have to be accepted as a price of aging, and their treatment need not be the same as treatment for night sweats.
Take cognitive and emotional difficulties seriously
Explain how a problem affects concentration, memory, mood or daily function rather than assuming a hormone test will settle it. Sleep disruption, symptoms, stress and other conditions can interact.
A progressive or substantial change deserves its own assessment. Hormone therapy should not be presented as a general treatment for every cognitive complaint. The next useful step is a clearer description and a plan that addresses the actual difficulty.
Fat, muscle and metabolism
Body composition describes the tissues contributing to body mass. It is different from body weight alone. Fat distribution, lean tissue, muscle strength and bone density are also distinct measurements.
What the menopause-transition research shows
In the longitudinal Study of Women’s Health Across the Nation (SWAN), researchers observed faster fat gain and declining lean mass around the menopause transition. They did not observe a corresponding acceleration in total weight gain at the transition.[7]
This finding illustrates how tissue changes can be partly hidden by the total on the scale. It describes an average pattern in the studied cohort, not a fixed prediction for every person. Observational data also do not establish that a single hormone explains the whole change.
Abdominal change is not a diagnosis by appearance
Changes in fat distribution around menopause can be relevant to metabolic health, but a body shape does not provide a hormone diagnosis. Discuss the appropriate health measures for your situation rather than trying to estimate internal fat or hormone levels from a photograph.
Weight, waist measurements and blood tests can answer different questions. A clinician may consider several together when assessing risk. None should become a judgement about effort or character.
| Measure or observation | What it describes | What it does not establish alone |
|---|---|---|
| Body weight | The total mass measured at that time. | How much of a change is fat, lean tissue, fluid or another component. |
| Lean mass estimate | A measurement category that includes more than skeletal muscle. | A direct diagnosis of muscle weakness or sarcopenia. |
| Strength or a familiar functional task | Performance in the particular task and testing conditions. | The cause of a decline or the level of a specific hormone. |
| Bone mineral density | One important component of a bone-health assessment. | The entire risk of fracture or proof that a treatment prevents fractures. |
| A symptom or hormone result | A piece of clinical information requiring context. | A complete explanation of metabolism, wellbeing or future health. |
Muscle loss and sarcopenia need careful language
Sarcopenia is assessed through measures of strength, muscle quantity or quality and physical performance. The European EWGSOP2 consensus places low muscle strength at the centre of assessment.[8] A change in a body-composition estimate alone does not establish the diagnosis.
If a familiar task is becoming difficult, describe the task and the change. Carrying shopping, getting up or managing stairs may reveal a practical problem worth assessing, but the cause should not be assumed to be estrogen or testosterone alone.
There is no single midlife metabolic switch
Energy needs and body composition reflect several influences, including activity, body size, illness, diet and treatment. A claim that a birthday or menopause suddenly “breaks metabolism” is too simple to guide a useful decision.
Choose a goal that can be supported directly: maintaining strength, meeting nutritional needs, managing a relevant health risk or making an activity more manageable. If intentional weight change is part of care, consider how to protect muscle, bone and adequate nourishment along the way.
The purpose is a healthier, more capable life. A particular silhouette is not a prerequisite for that goal.
Bone health and fracture risk
Estrogen helps regulate bone turnover. Its decline around menopause can increase bone loss, but fracture risk depends on more than one hormone or one scan. Previous fractures, age, falls, medicines and other health conditions also matter.[9]
A person can have low bone density without obvious symptoms. Ask about assessment when your history or clinical situation suggests a need; do not use the absence of pain as proof that bone health requires no attention.
Discuss the whole risk picture
Tell the clinician about fractures after relatively minor trauma, relevant medicines, falls and any history of early ovarian insufficiency or established hypogonadism. These details may change the assessment and management plan.
Bone-density testing and fracture-risk tools are used for particular clinical questions. Testing schedules and treatment decisions depend on the person and the local care pathway, rather than a universal instruction to scan everyone at the same age.
Strength and impact training require an appropriate starting point
The LIFTMOR randomised trial studied supervised resistance and impact training in screened postmenopausal women with low bone mass. It found improvements in bone-density and functional outcomes.[10]
That result supports the potential value of a well-designed programme. It does not show that every person with osteoporosis should copy heavy lifting or jumping without assessment, and the study did not establish a reduction in fractures.
If you have a vertebral fracture, substantial fracture risk, pain or uncertainty about loading, ask for suitable exercise guidance. The answer should describe movements and progression appropriate to your situation.
Support nutrition and ordinary movement
Calcium, vitamin D and adequate nutrition are relevant to bone health. Supplements should address a need within the wider diet and care plan, rather than serve as a universal high-dose routine.[9]
Also consider balance, vision, footwear, lighting and the practical circumstances of movement. A useful bone-health plan should help you stay active appropriately while addressing the situations in which a fall or injury might occur.
Keep treatment outcomes distinct
A medicine that improves bone density has not necessarily been shown to prevent fractures in every setting. The testosterone evidence discussed below provides an important example of that distinction.
If a clinician recommends an osteoporosis medicine or hormone treatment for a specific indication, ask what outcome it is intended to improve, how it will be reviewed and what other parts of the plan remain necessary.
Testosterone and aging
Testosterone contributes to sexual function, red-blood-cell production, muscle and bone. Its concentration can vary with health and measurement conditions. Some men develop clinically important deficiency; others maintain adequate levels into later life.
The European Association of Urology describes hypogonadism as a clinical syndrome involving relevant symptoms or signs and biochemical evidence of deficiency. It also distinguishes problems arising in the testes from problems in the hormonal signals that stimulate them.[2]
Why “male menopause” is an incomplete analogy
There is no single age at which every man stops producing testosterone or becomes infertile. A gradual average change across a population cannot diagnose an individual, and “andropause” should not replace a proper assessment.
Calling every change in energy, mood or body shape a hormone deficiency also risks missing other causes. The Endocrine Society’s 2026 statement emphasises that these symptoms can have several explanations and that reversible contributors should be considered.[11]
Describe sexual symptoms without assuming one cause
Reduced sexual desire, changes in erections and other sexual concerns can be relevant to the assessment, but they are not interchangeable symptoms. Tell the clinician what has changed, whether it is persistent and whether it causes distress or difficulty.
There is no required frequency of sexual activity or level of desire that everyone must meet. The aim is to understand a concerning change in the person’s own context, including health, treatment, relationships and preferences.
Consider the wider clinical picture
Illness, obesity and some medicines can affect testosterone or contribute to similar symptoms. Addressing a relevant contributor may be part of treatment, but it should follow an assessment rather than a generic instruction to lose weight or try harder.
If a person has a disease affecting the testes, pituitary or hypothalamus, the clinical question differs from an isolated lower result during illness. The cause matters for treatment and for what else needs evaluating.
Keep body composition in proportion
A change in muscle or abdominal fat can be one reason to review health, but it does not reveal a testosterone level. Conversely, increasing a laboratory value does not automatically restore strength, eliminate fatigue or resolve every metabolic problem.
Use symptoms, appropriate tests and everyday function together. This keeps the focus on the problem that needs help rather than on achieving the highest possible number.
Diagnosing testosterone deficiency
The Endocrine Society recommends diagnosing hypogonadism in men only when compatible symptoms or signs occur alongside unequivocally and consistently low testosterone concentrations. An initial morning fasting total-testosterone measurement should be confirmed with a repeat measurement using a reliable assay.[12]
The purpose is to establish a clinical diagnosis, not to find a justification for a product. A result near a boundary deserves interpretation, including the laboratory method and the circumstances of testing.
Tell the clinician about the test conditions
Include recent illness, medicines, sleep and work patterns. For people working shifts, the relationship between sampling and the main sleep period may require particular consideration. The EAU guideline addresses testing after adequate sleep and the interpretation of measurements in context.[2]
Do not try to manipulate sleep, food or exercise before a test to produce a desired result. Ask how to prepare and follow the testing instructions.
Total and free testosterone answer related questions
Much circulating testosterone is bound to proteins, including sex hormone-binding globulin (SHBG). When total testosterone is borderline or binding proteins are altered, an appropriate free-testosterone assessment may help interpretation. The method matters; not every reported “free testosterone” result is equally suitable.[12]
The clinician may also investigate the signals between the brain, pituitary and testes, or other possible causes. A low result is the beginning of that reasoning, not the end.
A symptom questionnaire is not a diagnosis
Checklists can help describe concerns, but fatigue, sleep difficulty or reduced confidence can occur for many reasons. A commercial questionnaire that labels a large range of ordinary experiences “low testosterone” cannot replace assessment.
The 2026 Endocrine Society statement highlights laboratory standardisation and the need for appropriate testing. It does not support indiscriminate screening of men without relevant symptoms.[11]
Ask what a result changes
Useful questions include: Is this result confirmed? Does it fit the symptoms? Is there a likely cause? Could another condition or treatment explain it? What benefit would treatment realistically aim to provide?
Ask for the result and its interpretation in a form you can keep. A number with units, the laboratory reference information and the clinical explanation is more useful than a label such as “suboptimal.”
Keep fertility goals visible from the start
Tell the clinician if you hope to have children. Testosterone treatment can suppress sperm production and is unsuitable for men actively pursuing fertility in the way ordinary replacement is often prescribed.[2] A specialist may consider a different approach depending on the cause of the problem.
Do not assume that a treatment promoted for sexual wellbeing will also support fertility. These are different outcomes and need different discussions.
What testosterone treatment can and cannot do
Testosterone replacement can be appropriate for men with established hypogonadism. The choice of preparation, dose and monitoring belongs within a clinical plan. The goal is to treat the deficiency and its relevant effects, rather than pursue bodybuilding doses or a universal promise of renewed youth.
Benefits differ across outcomes
In the Testosterone Trials, older men with low testosterone and relevant symptoms received testosterone or placebo for one year. Treatment improved sexual activity and related sexual outcomes, but did not significantly improve the prespecified primary vitality outcome.[13]
This matters when the main concern is tiredness. A treatment can help one outcome without reliably helping another. “More energy, better mood and more strength” should not be presented as a package that every patient can expect.
Changes in lean tissue or bone measurements also need to be separated from changes in daily performance. Ask what improvement the treatment is expected to make in your situation and how that improvement will be assessed.
Cardiovascular evidence is more specific than “safe” or “unsafe”
The TRAVERSE randomised trial studied testosterone gel in men with symptoms, repeated low testosterone and existing cardiovascular disease or a high cardiovascular risk. Testosterone met the trial’s prespecified non-inferiority criterion for major cardiovascular events compared with placebo: the main outcome was no worse than placebo within the trial’s predefined margin.[14]
That finding concerns the monitored treatment, population and follow-up studied. It does not establish that every dose, preparation or pattern of use is free of cardiovascular risk. Higher incidences of atrial fibrillation (an irregular heart rhythm), acute kidney injury and pulmonary embolism (a blood clot in the lungs) were observed in the testosterone group.[14]
In 2025, the U.S. FDA revised testosterone labelling following TRAVERSE and blood-pressure monitoring studies. It removed certain cardiovascular boxed-warning language while requiring blood-pressure warnings based on the new evidence.[15] This illustrates why a changed warning does not mean that all monitoring is unnecessary.
Better bone density did not translate into fewer fractures
In the TRAVERSE fracture substudy, testosterone did not reduce clinical fractures compared with placebo; fractures occurred more often in the testosterone group.[16] Testosterone should therefore not be presented as a proven substitute for an osteoporosis treatment plan.
Ask separately about bone-health assessment and fracture prevention when these are relevant. The same hormone can affect several tissues without providing the same clinical benefit in each.
Monitoring is part of the treatment
Testosterone can raise haematocrit, the proportion of blood volume occupied by red blood cells. Treatment requires review of the clinical response, hormone measurements and relevant safety measures. Prostate-related assessment, fertility, cardiovascular health and other contraindications also enter the decision.[12]
Agree who will organise follow-up, what changes require contact and what will happen if the intended benefit does not appear. Continuing indefinitely because a blood level increased is not a complete review.
Keep the individual decision open
Evidence supports appropriate treatment for an established deficiency while leaving important limits and uncertainties. The 2026 Endocrine Society statement calls for longer-term research and continued attention to diagnosis and safety.[11]
A good treatment discussion should make both the intended benefit and the uncertainty understandable. It should also leave room for the person to ask questions and reconsider the plan.
Menopausal hormone therapy options
Menopausal hormone therapy (MHT), also widely called HRT, includes treatments with different formulations and routes. A systemic estrogen treatment, a low-dose vaginal product and a compounded mixture should not be treated as interchangeable.
Systemic treatment addresses symptoms across the body
Systemic hormone therapy is the most effective treatment for menopausal hot flushes and night sweats and can prevent bone loss and fractures while used in appropriate candidates. The treatment decision depends on the indication, age, time since menopause, health history and formulation.[17]
Estrogen may be supplied through the skin, such as a patch or gel, or by an oral preparation. The route can affect the risk profile and practical use; it is a clinical choice rather than simply a preference between convenient formats.
The uterus changes the prescription
For someone with a uterus, systemic estrogen generally needs an appropriate progestogen to protect the endometrium, the uterine lining. Estrogen-only systemic therapy is generally used after hysterectomy, with exceptions requiring individual consideration.[18] Low-dose local vaginal estrogen is a different situation and generally does not require a progestogen.[3]
The exact product and regimen matter. Do not assume that an over-the-counter progesterone cream provides the protection required by a systemic prescription.
| Approach | Typical purpose | A distinction to discuss |
|---|---|---|
| Systemic estrogen with the required endometrial protection | Relief of appropriate menopause symptoms, with bone effects also relevant to the decision. | The presence of a uterus, health history, route and regimen shape the prescription. |
| Systemic estrogen after hysterectomy | Treatment of a suitable indication when estrogen-only therapy is appropriate. | The surgical and medical history still matters; hysterectomy does not remove every treatment risk. |
| Low-dose local vaginal estrogen | Treatment directed at vaginal and related genitourinary symptoms. | It is not interchangeable with systemic treatment for hot flushes or a general bone-protection prescription. |
| Non-hormonal treatment | Relief of a particular symptom when preferred or clinically appropriate. | Evidence and monitoring depend on the treatment and the symptom being addressed. |
Local treatment may fit a local problem
If vaginal symptoms are the main concern, a local treatment may be more appropriate than starting systemic therapy. Low-dose vaginal estrogen can relieve dryness and discomfort; some people using systemic therapy also need a local treatment.[6]
Report persistent irritation, pain or urinary symptoms so that other causes can be considered. If there is a history of hormone-sensitive cancer, decisions about local prescription treatment should involve the relevant care team.
Hormone therapy is not contraception
A person can still need contraception during perimenopause. The chosen contraception and hormone treatment should be reviewed together. Ask for a clear explanation of which treatment addresses symptoms and which, if any, prevents pregnancy.[1]
Choose a goal that can be reviewed
Before starting treatment, describe the main problem and the improvement you hope for. Fewer disrupted nights, less discomfort or better ability to manage the day can be meaningful outcomes.
Ask how long the chosen treatment usually needs before review, which side effects to report and what alternatives are available if it does not fit. A plan with a purpose and a review point is easier to evaluate than a promise to “balance everything.”
Benefits, risks and treatment review
The benefit-risk discussion should identify the treatment, the reason for using it and the person’s circumstances. A statement about “HRT risk” without those details leaves important questions unanswered.
Timing matters, but it is not a guarantee
The Menopause Society’s 2022 statement describes a generally more favourable balance for suitable symptomatic women younger than 60 or within 10 years of menopause onset, without contraindications. Starting later generally involves higher absolute risks. Continuing treatment is a separate decision requiring an ongoing indication and periodic review.[17]
These descriptions do not make treatment automatically suitable below a particular birthday or require everyone to stop on one. Ask how your own history changes the balance.
Discuss the risk relevant to the formulation
Blood clots, stroke, breast cancer, endometrial effects and other adverse effects must be considered according to the treatment. Personal cancer history, unexplained bleeding, liver disease or previous vascular events can change whether systemic therapy is appropriate or require specialist input.[18]
Transdermal estrogen may offer advantages over oral treatment for some risk profiles. It should still be assessed as a medicine with a particular indication and monitoring plan, rather than described as risk-free.[18]
Breast-cancer evidence cannot be reduced to one slogan
Long-term follow-up of the Women’s Health Initiative trials found higher breast-cancer incidence with the studied estrogen-plus-progestin regimen compared with placebo. In the separate trial involving women with prior hysterectomy, the studied estrogen-only regimen was associated with lower incidence compared with placebo.[19]
These were different trial populations and specific oral formulations. The finding is not a direct comparison of every modern regimen and does not justify a claim that estrogen prevents breast cancer. The actual product, duration and personal history belong in the discussion.
Ask for absolute risk when a number is offered
“A relative increase” is difficult to interpret without a starting risk and a time period. Ask how many additional events might occur among a stated number of comparable people over a stated duration, and how certain that estimate is.
Also ask about the benefit being compared with that risk. An improvement in daily symptoms may be very important to one person, while another may prefer a different option. Informed decisions need both the evidence and the person’s priorities.
Do not turn symptom treatment into a general prevention promise
Hormone therapy should not be prescribed simply as a universal strategy to prevent cardiovascular disease or dementia, or to reverse aging.[17] A treatment may have a specific preventive role, such as in selected bone-health or early ovarian-insufficiency circumstances, without becoming an all-purpose longevity treatment.
Review the plan when the situation changes
Agree what to do about unexpected bleeding, persistent side effects or new medical diagnoses. Tell the prescriber about all medicines and supplements, and ask before making dose changes.
At review, consider whether the original goal is being met, whether the treatment still fits and whether another option would be preferable. A decision to continue, adjust or stop should be understandable and shared.
Non-hormonal symptom treatments
People who cannot use hormone therapy, prefer another approach or need treatment for a different symptom still have options. The relevant question is what has evidence for the particular problem, in the person’s circumstances.
Hot flushes and night sweats
The Menopause Society’s 2023 statement supports selected non-hormonal approaches, including menopause-focused cognitive behavioural therapy, clinical hypnosis and certain prescription medicines. Options include some antidepressant medicines (SSRIs or SNRIs), gabapentin and medicines targeting brain signalling involved in temperature control; suitability depends on the person and local availability.[20]
A medicine used in another area of care may also have evidence for vasomotor symptoms. Its use should be explained in terms of the symptom being treated, expected benefit, side effects and interactions.
A newer mechanism still needs a safety plan
Fezolinetant, marketed in the EU as Veoza, is a non-hormonal treatment for moderate-to-severe menopause-related vasomotor symptoms. European safety communications require attention to liver injury and liver-function testing before and during treatment.[21]
This is an example of why “non-hormonal” does not mean that a medicine has no risks. Ask which tests, symptom checks and follow-up are required for the specific product. Newer options should be assessed using current product information, not only an early announcement.
Vaginal discomfort and urinary symptoms
Lubricants used for sexual activity and moisturisers used regularly can help with different aspects of dryness. Persistent symptoms may need prescription treatment or assessment for another cause.[6]
Choose an approach that addresses the actual discomfort and respects the person’s preferences. Painful sexual activity should not be treated as something to endure to preserve intimacy; discuss comfortable alternatives and appropriate care.
Distinguish comfort measures from proven symptom treatment
Adjusting clothing or the sleeping environment may make a day or night more comfortable. That practical value is different from proof that a technique consistently treats hot flushes.
The 2023 non-hormonal statement did not recommend exercise, yoga, mindfulness or herbal supplements specifically as evidence-based vasomotor treatments.[20] This does not negate other reasons to enjoy activity or a calming practice. It means those activities should not be promised as a reliable replacement for symptom treatment.
Review one clear question at a time
If the main problem is repeated night waking, ask whether hot flushes, insomnia, another sleep condition or several factors are involved. If the main problem is dryness, a treatment aimed only at hot flushes may leave it unresolved.
Choose a way to judge the response that fits the symptom. Record enough to support the review without turning each day into continuous health monitoring.
Movement, nourishment and recovery
Exercise, adequate food and recovery support health throughout midlife and later life. Their value does not depend on making hormone levels resemble those of a younger person. They can remain useful whether or not a hormone treatment is part of care.
Give strength training a practical purpose
Choose movements that support tasks or activities you value, with resistance and support appropriate to your current ability. A well-designed plan describes the exercises, amount, effort and progression. It can use machines, free weights, bands, body weight or suitable adaptations.
Ask for help if pain, fracture risk, a recent operation or another health condition makes the starting point unclear. Progress should reflect the response and the relevant clinical advice, rather than a rule that everyone must lift heavily at a particular age.
Combine different kinds of movement
WHO’s general adult targets include 150–300 minutes of moderate aerobic activity, or 75–150 minutes of vigorous activity, or an equivalent combination weekly, plus muscle-strengthening activity on at least two days. For older adults, varied activity emphasising functional balance and strength on three or more days is also recommended according to ability.[22]
These are population targets, not an instruction to reach them immediately. An appropriate starting amount may be smaller. Include activities you can access and repeat, and adjust the challenge when health or circumstances change.
Aerobic activity need not be a race, and strength practice need not be a test of maximal lifting. Walking, wheeling, cycling, dancing or another suitable activity can be organised around the person’s goals and available support.
Feed the work you want the body to do
Adequate energy, protein and overall nutrition matter, particularly when appetite is poor, weight is changing unintentionally or illness complicates eating. ESPEN’s guidance for older people emphasises individual nutrition assessment and the prevention and treatment of malnutrition.[23]
Build meals around foods you enjoy and can obtain. Include appropriate protein sources and a varied mix of foods that support nutritional needs. If a clinical condition affects protein, fluids or other dietary choices, use that advice to shape the plan.
A specialist menopause food, powder or restrictive diet is not required to make a nourishing meal. If you are considering supplements, identify the specific need, total intake and possible interactions first.
Make weight-related goals compatible with muscle and bone
If intentional weight loss is part of an agreed health plan, ask how to preserve adequate nourishment and useful strength. If weight is falling without intention, that is a different problem and deserves attention.
A change in body composition is not an instruction to keep eating less. Consider the actual health question, current intake, appetite, activity and functional goals before deciding what needs changing.
Protect sleep opportunity and investigate persistent difficulty
Make room for adequate sleep and a workable routine. Persistent night sweats may need symptom treatment; recurring sleep difficulty can also need a separate assessment. The National Heart, Lung, and Blood Institute describes cognitive behavioural therapy for insomnia as a usual first treatment for long-term insomnia.[24]
The point is to address the cause of the difficulty. More exercise, another supplement or more time in bed may not answer every sleep problem.
Make the routine flexible enough to continue
On a disrupted day, an appropriate shorter activity may be more manageable. After illness or a substantial break, revisit the starting point. Keep the goal while adjusting the amount, timing or support.
Review function and participation alongside symptoms: whether you can manage ordinary tasks, return to a valued activity or keep a satisfying routine. Those outcomes deserve attention even when a scale or hormone value changes little.
Claims, testing and future research
Hormone science continues to develop, but the language used to sell a treatment can move faster than the evidence. Terms such as “natural,” “optimised,” “personalised” and “bioidentical” need a specific explanation before they can inform a decision.
Bioidentical describes a molecule, not a guarantee
Estradiol and progesterone in licensed medicines can be chemically identical to hormones produced by the body. That does not make every product marketed as bioidentical equivalent.
ACOG’s clinical consensus distinguishes regulated products from compounded bioidentical menopausal hormone preparations and advises against routine use of compounded therapy when approved alternatives are available. Claims that customised mixtures are inherently safer or more effective lack adequate supporting evidence.[25]
Ask which exact hormones are supplied, whether the product is authorised for the intended use, how the dose is controlled and why that preparation is being recommended. A persuasive name cannot answer those questions.
A personalised-looking test does not establish a personalised treatment
A large saliva, urine or blood panel can generate many numbers without showing which treatment will help. ACOG also cautions against using adjunct hormone testing to prescribe and dose compounded menopausal therapy because the supporting evidence is limited.[25]
Testing can be appropriate for a defined clinical question. The test should have a clear purpose, a suitable method and an interpretation that changes care in a useful way. This is different from adjusting every result towards a commercial “optimal” range.
Testosterone for women is a separate clinical question
The international consensus on testosterone therapy for women identifies an evidence-based role for postmenopausal women with hypoactive sexual desire disorder after appropriate assessment. This involves persistently low desire associated with distress, evaluated in its wider context. A testosterone blood value alone does not diagnose it.[26]
That indication does not establish testosterone as a general treatment for fatigue, muscle building, cognition or aging in women. Treatment, where appropriate, needs suitable dosing and monitoring; a male replacement regimen should not be copied.
Ask what an innovation improves
For a new medicine, delivery system or biomarker-guided programme, ask whether research shows symptom relief, better function or fewer important health events. A laboratory change alone may not answer those questions.
Look for an appropriate comparison, a relevant population, sufficient follow-up and clear reporting of adverse effects. Findings in cells, animals or a small selected group should not be presented as established benefits for everyone.
Keep uncertainty visible without losing useful options
Evidence may support one use strongly while leaving another uncertain. A treatment can deserve a place in care without becoming a universal solution. It can also be reasonable to seek a better explanation before accepting a broad claim.
Future progress will be most useful when it clarifies who benefits, which outcomes improve, what harms occur and how people can access appropriate care. Those are stronger measures of progress than the size of a testing panel or the confidence of an advertisement.
A practical plan and examples
This original five-step framework can help organise a discussion and a review. It is not a diagnostic instrument or a hormone-treatment protocol.
-
Describe the change and why it matters.
State the symptom or functional difficulty in ordinary language. Include when it began and how it affects the day.
-
Bring the relevant context.
Include menstrual or surgical history where relevant, medicines, sleep, illnesses and any prior tests. Mention fertility goals before a treatment decision.
-
Choose a clear question for assessment.
Ask whether the pattern fits a hormonal transition, whether another cause needs investigating and which tests, if any, would help.
-
Agree a plan with a purpose and a review point.
Clarify the intended benefit, alternatives, important risks, practical instructions and who will organise follow-up.
-
Review the response and adjust thoughtfully.
Consider symptoms, daily function and the relevant safety information. Keep, change or reconsider the plan according to what the review shows.
| Question | A useful note |
|---|---|
| What is the main problem? | The specific symptom or activity that has become difficult. |
| What else is relevant? | Recent changes, medicines, menstrual or surgical history, sleep and existing care. |
| What decision do I need help with? | Whether assessment, testing, symptom treatment or another form of support is appropriate. |
| What did we agree? | The purpose of the plan, instructions, important risks and review arrangements. |
| What happened afterwards? | The response in the relevant symptom and everyday life, plus any issue to report. |
Fictional example: disrupted sleep during perimenopause
A person in midlife reports irregular periods and repeated night sweats. They have been told to buy a large hormone-testing panel before anyone can discuss treatment.
They describe the pattern, current contraception and effect on daily life to a clinician. The assessment considers whether the history fits perimenopause, whether anything else needs investigating and which treatment options match the symptoms and health history.
The plan includes a clear review of night-time symptoms and how the day feels. This example does not presume that testing is never useful or that hormone therapy is automatically the right choice.
Fictional example: tiredness and one low testosterone result
A man notices persistent tiredness and receives a low testosterone result from a sample taken during an illness. An advertisement offers immediate treatment with promises of more energy and rapid muscle gain.
He discusses the symptoms, illness, medication and testing conditions with a clinician. Appropriate repeat testing and evaluation of possible causes come before a treatment decision. Fertility goals are included if relevant.
The question is whether a confirmed deficiency explains part of the problem and what treatment could reasonably improve. Raising the number is not assumed to resolve every cause of fatigue.
Fictional example: body changes and a bone-health concern
A person after menopause notices a change in body shape and has had a fracture after a relatively minor fall. They are considering a restrictive diet and a product advertised to rebuild bone by “balancing hormones.”
The fracture prompts an appropriate bone-health assessment. The activity and nutrition plan is reviewed alongside any indicated medical treatment, with attention to strength, falls and adequate nourishment.
The review considers the clinical plan and daily function. Neither a lower scale weight nor an improved hormone result is treated as proof of fracture prevention.
These are fictional teaching examples. They demonstrate questions and decisions, not documented patient histories or guaranteed treatment outcomes.
Support can be practical and respectful
A partner, friend or family member can help by listening, offering practical assistance and respecting privacy. Ask what would be useful rather than deciding which symptom or treatment should matter most.
If you feel a concern has not been understood, bring a clearer account, ask what explanation is being considered or seek another appropriate clinical opinion. The goal is a usable answer and a plan you understand.
Common questions
Is menopause diagnosed by one blood test?
Usually, typical menopause or perimenopause after age 45 is assessed from the history and symptoms without routine hormone testing. Tests have a different role when the age, symptoms or circumstances suggest another cause or premature ovarian insufficiency.
Can I ask for treatment before my periods have stopped for a year?
Yes. Troublesome symptoms can be assessed during perimenopause. The appropriate options depend on the symptom, medical history, bleeding pattern and contraception needs.
Does menopause inevitably cause substantial weight gain?
No single amount of weight gain is inevitable. Research shows that fat and lean tissue can change during the transition without a matching acceleration in total weight. Review relevant health measures, nourishment, strength and function rather than assuming a fixed outcome.
Will exercise stop hot flushes?
Exercise has important health and functional benefits, but it is not established as a consistently effective treatment for hot flushes. If symptoms are disruptive, discuss treatments with evidence for that purpose while keeping suitable activity in the wider plan.
Is andropause the male equivalent of menopause?
The comparison is incomplete. Men do not universally undergo a timed cessation of testosterone production. Possible hypogonadism requires assessment of relevant symptoms and consistently low testosterone, including investigation of the cause.
Is one low testosterone result enough to start replacement?
An isolated result usually needs confirmation and clinical interpretation. Appropriate repeat testing, the laboratory method, symptoms, illness, medicines and other relevant factors should be considered before deciding on treatment.
Can testosterone treatment affect fertility?
Yes. Testosterone supplied from outside the body can suppress sperm production. Tell the clinician about fertility goals before treatment; a different specialist approach may be needed.
Is low-dose vaginal estrogen the same as systemic HRT?
No. Low-dose local vaginal treatment targets genitourinary symptoms and has a different exposure and treatment role. It is not a replacement for systemic therapy for hot flushes or a general bone-protection prescription. The specific product and medical history still matter.
Are compounded bioidentical hormones safer?
That claim is not supported by adequate evidence. Licensed medicines can also contain hormones identical to those made by the body. Product quality, dose, indication and monitoring matter more than the marketing term.
Should hormone treatment be taken indefinitely?
There is no universal duration for every indication and person. Review the intended benefit, response, risks and alternatives with the prescriber. POI, ordinary menopause symptom treatment and male hypogonadism raise different long-term care questions.
Sources and scope
Sources checked 6 September 2026. This guide draws on European and international professional guidance, official patient information, observational research and randomised clinical trials. It is educational and does not provide an individual diagnosis, hormone dose or treatment prescription.
Menopause, premature ovarian insufficiency and male hypogonadism are distinct situations. A treatment recommendation for one should not be transferred to another. Anatomy, symptoms, fertility goals, medical history and the actual product affect the decision.
SWAN describes longitudinal body-composition patterns and does not prove that one hormone causes every change. The Testosterone Trials and TRAVERSE concern their particular populations, formulations and outcomes. Bone-density changes should not be substituted for fracture evidence. The two Women’s Health Initiative hormone trials involved different populations and specific regimens.
The tables, planning framework and fictional scenarios are original explanatory material. They are not validated diagnostic tools or clinical case reports. Treatment authorisation and service access vary by country, and current local product information governs practical prescribing details.
The references provide a basis for checking and updating the article as guidance develops. Where a current clinical decision is involved, use the source relevant to that decision and the advice of the responsible healthcare professional.
- World Health Organization. Menopause. Fact sheet; 16 October 2024.Definitions, variation in the menopause experience, and the distinction between symptom treatment and contraception. Return to text ↑
- European Association of Urology. EAU Guidelines on Sexual and Reproductive Health: Male Hypogonadism. 2026 guideline.Clinical definitions, testing circumstances, fertility and individual treatment considerations. Return to text ↑
- Lumsden MA, Dekkers OM, Faubion SS, et al.; European Society of Endocrinology. Clinical practice guideline for evaluation and management of menopause and the perimenopause. European Journal of Endocrinology. 2025.European guidance on diagnosis, testing, early ovarian insufficiency and hormonal and non-hormonal management. Return to text ↑
- ESHRE, ASRM, International Menopause Society and CRE WHiRL. Premature Ovarian Insufficiency: A Guide for Women. Patient version of the international guideline; December 2024.Explains POI, hormone treatment, fertility and care until the usual menopause age; prescribing details are not reproduced here. Return to text ↑
- National Institute on Aging. What Is Menopause?. Official patient information; 16 October 2024.Supports the description of common symptoms and the changing menstrual pattern. Return to text ↑
- The Menopause Society. Genitourinary Syndrome of Menopause. MenoNote patient information; May 2025.Distinguishes local symptoms, nonprescription measures and appropriate prescription options. Return to text ↑
- Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. doi:10.1172/jci.insight.124865.Longitudinal SWAN cohort findings; average tissue changes are not an individual forecast or proof of a single hormonal cause. Return to text ↑
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48(1):16–31. DOI: 10.1093/ageing/afy169.EWGSOP2 framework distinguishing muscle strength, quantity or quality, and physical performance. Return to text ↑
- The North American Menopause Society, now The Menopause Society. Postmenopausal Osteoporosis. MenoNote patient information; 2022.Bone loss, fracture-risk assessment, nutrition and the distinction between general measures and osteoporosis treatment. Return to text ↑
- Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. The LIFTMOR trial: resistance and impact training in postmenopausal women with low bone mass. Journal of Bone and Mineral Research. 2018;33(2):211–220. DOI: 10.1002/jbmr.3284.Randomised trial in 101 screened women, with supervised higher-intensity training. Bone-density and function findings do not directly demonstrate fracture prevention. Title abbreviated. Return to text ↑
- Endocrine Society. Statement on Testosterone Replacement Therapy. Professional statement; 16 July 2026.Current statement on diagnostic quality, appropriate treatment, remaining safety questions and longer-term research. Return to text ↑
- Endocrine Society. Testosterone Therapy in Men With Hypogonadism: Guideline Resources. Clinical practice guideline; 19 March 2018.Diagnosis requires compatible findings and consistently low testosterone; covers testing, contraindications and monitoring. Return to text ↑
- Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. New England Journal of Medicine. 2016;374:611–624. doi:10.1056/NEJMoa1506119.Randomised Testosterone Trials; sexual outcomes and the prespecified vitality result should be interpreted separately. Return to text ↑
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine. 2023;389:107–117. doi:10.1056/NEJMoa2215025.TRAVERSE assessed monitored gel treatment in symptomatic men with confirmed low testosterone and cardiovascular disease or high risk. Return to text ↑
- U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. Safety communication; 28 February 2025.Documents the 2025 cardiovascular-label changes and blood-pressure warning. It is not used as a statement of Lithuanian prescribing rules. Return to text ↑
- Snyder PJ, Bauer DC, Ellenberg SS, et al. Testosterone Treatment and Fractures in Men with Hypogonadism. New England Journal of Medicine. 2024;390:203–211. doi:10.1056/NEJMoa2308836.TRAVERSE fracture substudy found no reduction in clinical fractures; observed fracture incidence was higher with testosterone. Return to text ↑
- The North American Menopause Society, now The Menopause Society. The 2022 hormone therapy position statement. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028.Professional guidance on indications, timing, benefits, risks and ongoing individual review. Return to text ↑
- The Menopause Society. Menopause Topics: Hormone Therapy. Official patient information.Used for distinctions between systemic preparations, uterine protection, routes and relevant medical history. Return to text ↑
- Chlebowski RT, Anderson GL, Aragaki AK, et al. Menopausal hormone therapy and breast-cancer outcomes during long-term follow-up of the WHI trials. JAMA. 2020;324(4):369–380. doi:10.1001/jama.2020.9482.Follow-up of two separate randomised trials with different populations and specific oral regimens. Title abbreviated. Return to text ↑
- The North American Menopause Society, now The Menopause Society. The 2023 nonhormone therapy position statement. Menopause. 2023;30(6):573–590.Evidence-based options for vasomotor symptoms; absence of a recommendation for that symptom does not negate other benefits of activity. Return to text ↑
- Health Products Regulatory Authority, Ireland. Veoza (fezolinetant): liver-injury risk and liver-function monitoring. European medicine-safety communication; 13 January 2025.Highlights liver-function assessment before and during treatment; current product information provides the prescribing details. Return to text ↑
- World Health Organization. WHO Guidelines on Physical Activity and Sedentary Behaviour: Recommendations. 2020 guideline, recommendations chapter.Public-health activity targets for relevant adult populations, with adaptation to ability and clinical circumstances. Return to text ↑
- Volkert D, Beck AM, Cederholm T, et al. ESPEN practical guideline: Clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2022;41:958–989.Professional guidance on nutrition, malnutrition risk and hydration in older people. Individual clinical needs govern dietary and fluid plans. Return to text ↑
- US National Heart, Lung, and Blood Institute. Insomnia: Treatment. Clinical information, checked 6 September 2026.Explains CBT-I components and delivery options, alongside considerations for sleep aids and other treatment. Return to text ↑
- American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy: Clinical Consensus No. 6. Obstetrics & Gynecology. 2023;142(5):1266–1273. doi:10.1097/AOG.0000000000005395.Distinguishes compounded products from regulated alternatives and addresses unsupported custom-dosing claims. Return to text ↑
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism. 2019;104(10):4660–4666. doi:10.1210/jc.2019-01603.Defines the evidence-based HSDD indication and limits of generalising testosterone use to other symptoms or outcomes. Return to text ↑
Care for the person through the change.
A useful understanding of hormones makes the next decision clearer: which symptom needs attention, what a test can explain, which treatment has evidence and how to protect the abilities you value.
Keep room for appropriate care, nourishing food, suitable movement and recovery. Your health is larger than a hormone level or a body measurement. Let the plan serve the life you want to keep living.